Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company, to assist in the design and development of the MagSense instrument platform for clinical applications.
View the ASX announcement, “Imagion Biosystems Initiates MagSense Instrument Development.”
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance